Publications
1. Cohen, D. and Nir, I. Cytochemical Evaluation of Anionic Sites on the Surface of Cultured Pigment Epithelium Cells From Normal and Dystrophic RCS rats. Exp. Eye Res. 37: 575-582, 1983.
2. Nir, I., Cohen, D. and Papermaster, D. S. Immunocytochemical Localization of Opsin Molecules in Cell Membrane of Developing Retinal Photoreceptors. J. Cell Biol. 98: 1788-1795, 1984.
3. Cohen, D. and Nir, I. Sialic Acid On The Surface of Photoreceptors and Pigment Epithelium in RCS Rats. Invest. Ophthal. Vis. Sci. 25: 1342-1345, 1984.
4. Malik, S., Cohen, D., Meyer, E. and Perlman, I. Light Demage In The Developing Retina of Albino Rats: An Electroretinographic Study. Invest. Ophthal. Vis. Sci. 27: 164-167, 1986.
5. Cohen, D. and Nir, I. Cytochemical Characterization of Sialoglycoconjugates on Rat Photoreceptor Cell Surface. Invest. Ophthal. Vis. Sci. 28: 640-645, 1987.
6. Nir, I. and Cohen, D. Surface Glycoconjugates of The Rat Photoreceptor Cilium. Invest. Ophthal. Vis. Sci. 28: 1070-1077, 1987.
7. Schechner, R. Gdal-on, M. Cohen, D. Meyer, E., Zonis, S. and Perlman, I. Recovery of Electroretinogram in Rabbit After Argon Laser. Invest. Ophthal. Vis. Sci. 1605-1613, 1987.
8. Cohen, D., Yang, C.-P. and Horwitz, S.B. Turnover Rates of Two Distinct P-glycoproteins In Independently Isolated Vinblastine-Resistant J774.2 Cell Lines. Life Sciences 46: 486-495, 1990.
9. (Hsu, S.I., Cohen, D.)*, Kirschner, L.S., Lothstein, L. and Horwitz, S.B. Structural Analysis of the Mouse mdr1a (P-glycoprotein) Promotor Reveals The Basis for Differential Transcript Heterogeneity in Multidrug-Resistant J774.2 Cells. Mol. Cell Biol. 10: 3596-3606, 1990. *The order of the first two authors is arbitrary
10. Yang, C.-P.H., Cohen, D., Greenberger, L.M., Hsu, S.I. and Horwitz, S.B. Differential Transport Properties of Two mdr Gene Products Are Distinguished by Progesterone. J. Biol. Chem. 265: 10282-10288, 1990.
11. Cohen, D., Piekarz, R., Hsu, S.I., DePino A. R., Carrasco, N. and Horwitz,S.B. Structural and Functional Analysis of the Mouse mdr1b Gene Promoter. J. Biol. Chem. 266: 2239-2244, 1991.
12. Greenberger, L.M., Hsu, S.I.-H., Yang, C.-P., Cohen, D., Lothestein, L., Han, E.k.-K., Kirshner, L.S., Piekarz, R.L., Yu, L. and Horwitz, S.B. A Comparison of the Structure,
Function and Expression of P-glycoprotein Encoded by mdr1a and mdr1b in Mouse. In: "Drug Resistance as a Biochemical Target in Cancer Chemotherapy" eds. Tsuruo, T., ogawa, M., and Carter, S.K. Academic Press, pp: 63-95, 1992.
13. Kirshner, L.S., Greenberger, L.M., Hsu, S.I.-H., Yang, C.-P., Cohen, D., Piekarz, R.L., Castilo, G., Yu, L., Horwitz, S.B. Biochemical and Genetic Characterization of the Multidrug Resistance (MDR) Phenotype in Murine Macrophage like J774.2 Cells. Biochemical Pharmacology, 43: 77-87, 1992.
14. Greenberger, L.M. Cohen, D. and Horwitz, S. B. In vitro Models of multiple drug resistance. In: Anticancer Drug Resistance: Advances in Molecular and Clinical Research, Goldstein, L.J., and Ozols, R.F. (eds) p 69-106, 1994.
15. Cohen, D., Higman, S.M., Hsu, S. I-H and Horwitz, S. B. The involvement of a LINE-1 element in a DNA rearrangement upstream of the mdr1a gene in a Taxol multidrug resistant cell line J. Biol. Chem. 267: 20248-20254 1992.
16. Yu, L., Cohen, D., Piekarz, R. and Horwitz, S.B. Three distinct nuclear protein binding sites in the promoter of the murine multidrug resistance mdr1b gene. J. Biol. Chem. 268: 7520-7526, 1993
17. Horwitz, S.B. Cohen, D., Rao, S., Ringel, I., Shen, H.-J. and Yang, C.-P. Taxol: Mechanisms of Action and Resistance. J. Natl. Cancer Inst. Monogr. 15: 55-61, 1993
18. Piekarz, R.L., Cohen, D. and Horwitz S. B. Progesterone regulates the murine multidrug resistance mdr1b gene. J. Biol. Chem. 268: 7613-7616, 1993.
19. Cao, C., Steinberg, T.H., Cohen, D., Horwitz, S.B., Hickman, S. and Silverstein, S.C. Probenecid resistant J774 cells expression of enhanced organic anion transport by a mechanism distinct from multidrug resistance. Infect. Agents & Disease 2: 193-200, 1993
20. Cohen, D., Yu, L., Rzepka R. and Horwitz, S.B. Identification of two nuclear protein binding sites and their role in the regulation of the murine multidrug resistance mdr1a promoter. DNA and Cell Biology 13: 641-649, 1994
21. Combates, N., Rzepka, R. and Cohen, D. NF-IL6, a member of the C/EBP family of transcription factors binds and trans-activates the Human MDR1 gene promoter. J. Biol. Chem. 269: 29715-29719, 1994
22. Archinal, A., Rezpka, RW., Watanabe, T. Kokubu, N., Itoh, Y., Combates, N., Bair, K. and Cohen, D. Analysis of the interactions of PSC 833, a multidrug resistance modulator, with P-glycoprotein Oncology Research 7: 603-610, 1995
23. Watanabe, T., Naito, M., Oh-hara, T., Itoh, Y., Cohen, D. and Tsuruo, T. Modulation of multidrug resistance by SDZ PSC 833 in leukemic an solid-tumor bearing nude mice. Jpn. J. Cancer Res. 87:184-193, 1996.
24. Combates, N., Kown, P., Rzepka, R and Cohen, D. The involvement of transcription factor NF-IL6 in Phorbol Ester Induction of P-glycoprotein. Cell Growth & Differentiation.8: 213-219, 1997.
25. Ehrlich, P.H., Moustafa, Z. A., Archinal, A., Newman, M.N., Bair, K. W. and Cohen, D. The reversal of multidrug resistance on multicellular tumor spheroids. Anticancer Res. 17: 129-134, 1997.
26. Kokubu, N., Cohen, D and Watanabe, T. Functional midulation fo ATPase of P-glycoprotein by C219, a monoclonal antibody against P-glycoprotein. Biochem. Bioph. Comm. 230, 398-401, 1997.
27. Watanabe, T., Kokubu, N., Charnick, S., Naito, M., Tsuruo, T. and Cohen, D. Inhibiton of Human P-glycoprotein ATPase activity by P-glycoprotein modulators. British J. Pharma. 122:241-248,1997.
28. Barbarics, E., Kronauge, J.F., Cohen, D., Davison, A., Jones, A.G., and Croop, J. Detection of P-glycoprotein reversal in vivo using [99mTc]Sestamibi. Cancer Res. 58: 276-282, 1998.
29. Atadja, P., Watanabe, T., Xu, H. and Cohen, D. PSC 833, a frontier in modulation of
P-glycoprotein mediated multidrug resistance. Cancer and Metastasis Reviews. Kluwer Academic Publishers. 17: 163-168, 1998.
30. Fischer, V., Gascon, A. R., Heitz, F., Tynes, R., Hauck, C., Cohen, D. and Vickers, A.E.M. The MDR modulator SDZ PSC 833 is metabolized by CYP3A: implications for drug-drug interactions. Drugs Metabolism and Disposition. The American Society for Pharmacology and Experimental Therapeutics 26: 802-811, 1998.
31. Emanuel, L.S., Chamberlin, H.A. and Cohen, D. Antimititic drugs cause increased tumorigenicity of multidrug resistant cells. Inter. J. Oncology 14: 487-494, 1999
32. Sambucetti, L. C., Fischer, D., D., Zabludoff, S., Kwon, P. O., Chamberlin, H. A., Trogani, N., Xu, H., and Cohen, D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 49: 34940-34947, 1999
33. G. K. C., Lacayo, N. J., Durán, G. E., Cohen, D. and Sikic, B. I. Loss of cyclosporin and Azidopine binding are associated with altered ATPase activity by a Mutant P-Glycoprotein with Deleted Phe335. Mol. Pharmacol. 57:569-777, 2000
34. Watanabe, T., Kokubu, N., Roninson I. B., Cohen, D. and Atadja, P. Altered Activity of MDR reversing agents on KB3-1 cells transfected with Gly185Val Human P-glycoprotein. Int. J. Oncology, 17:579-586, 2000
35.Cai, R, Yan-Neale, Y., Cueto, M., Xu, H. and Cohen, D. HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G2/M checkpoint rad proteins. J. Biol. Chem 275, 27909-27916, 2000
36. Cai, R., Fischer, D., Y, Yan-Neal., H. Xu and Cohen, D. Transcription regulation to cell cycle checkpoint. In: From Genome to Therapy: Integrating new technologies with drug development. Novartis Foundation, John Wiley & Sons, Ltd. p19-26, 2000
37. Flescher, E., Rotem, R., Kwon, P., Azare, J, and Cohen, D. Multidrug resistance gene 1 expression in human Molt-4 T lymphoma cells. AntiCancer Res. 20: 4441-4444, 2001
38. Cai, R., Kwon, P., Yan-Neale, Y., Sambuccetti, L., Fischer, D. and Cohen, D. Mammalian histone deacetylase 1 protein is posttranslationally modified by phosphorylation. Biochemical & Biophysical Research Communication 283: 445-453, 2001
39. Azare, J., Pankova-Kolmyansky, I., Salnikow, K., Cohen, D. and Flescher, E. Selective susceptibility of transformed T lymphocytes to induction of apoptosis by PSC 833, an inhibitor of P-glycoprotein. Oncol. Res. 12: 315-323, 2001
40. Uchiyama-Kokubu, N., Watanabe, T. and Cohen, D. Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and Cyclosporin A closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15. Jpn. J. Cancer Res. 92: 1116-1126, 2001
41. Fischer, D., Cai, R., Bhatia, U., Asselbergs, F. A. A., Song, C., Terry, R., Trogani, N., Widmer, R., Atadja, P., and Cohen, D. Isolation and characterization of a novel class I/II histone deacetylase, HDAC10, J. Biol. Chem. 277: 6656-6666, 2002
42. Atadja, P., Yan-Neale, Y., Towbin, H., Buxton, F. and Cohen, D. Gene expression profiling of epothilone a resistant cells. . In: Mechanisms of Drug Resistance in Epilepsy: Lessons from Oncology. Novartis Foundation, John Wiley & Sons, Ltd. p119-136, 2002
43. Kinzel, B., Hall, J., Natt, F., Weiler, J, and Cohen, D. Downregulation of Hus 1 by antisense oligonucleotides enhances the sensitivity of human lung carcinoma cells to cisplatin. Cancer 94: 1808-14, 2002
44. Zeremski, M., Stricker, J.R., Fischer, D., Zusman, S,B. and Cohen, D. Histone deacetylase dHDAC4 is involved in segmentation of the drosophila embryo and is regulated by gap and pair-rule genes. Genesis 35:31-38, 2003
45. Wang, S., Yan-Neale, Y., Fischer, D., Cai, R., Zhu, J., Burfeind, P., Hampton, G., and Cohen, D. Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line. Oncogene: 22: 6204-6213, 2003
46. V. Iourgenko, W. Zhang, C. Mickanin, I. Daly, C. Jiang, J. M. Hexham, A. P. Orth, L. Miraglia, J. Meltzer, D. Garza, G. Chirn, E. McWhinney, J. Skelton, R. Terry, Y. Yu, D. Bodian, F. P. Buxton, J. Zhu, C. Song, M. Labow and Cohen, D. Rapid Genome-Scale Functional Analysis in Mammalian Cells using Arrayed Full length cDNAs: Identification of TORCs, a Novel Family of CREB-CO-Activators, Proceedings of the National Academy of Sciences (PNAS), 100, 12147-12152, 2003
47. Chanda, S., White, S., Orth, T., Reisdorf, R., Miraglia, T., Thomas, R., DeJesus, P., Huang, Q., Mason, D., Vega, R., Yu, D., Nelson, C., Smith, B., Terry, R., Linford, A., Yu, Y., Chirn, G., Song, C., Labow, M., Cohen, D., King, F., Peters, E., Vogt, P., Schultz, P., Hogenesch, J., Caldwell, J., 2003. Genome-scale functional profiling of the mammalian AP-1 Signaling Pathway. Proceedings of the National Academy of Sciences, 100, 12153-12158
48. Atadja, P., Gao, L., Kwon, P., Trogani, N., Walker, H., Hsu, M., Yeleswarapu, L., Chandramouli, N., Perez, L., Versace, R., Wu, A., Sambucetti, L., Lassota, P., Cohen, D., Bair, K., Wood, A., Remiszewski, S., 2004. Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor NVP-LAQ824. Cancer Research, 64:689-695
49. Dieter Huesken, Joerg Lange, Craig Mickanin , Jan Weiler, Fred Asselbergs, Justin Warner, Brian Meloon, Sharron Engel, Avi Rosenberg, Dalia Cohen, Mark Labow, Mischa Reinhardt, François Natt and Jonathan Hall An artificial neural network for the design of a genome-wide siRNA library. Nature Biotechnology, 23:995-1001, 2005
50. Shaowen Wang, Yan Yan-Neale, Richard Cai, Irina Alimov and Dalia Cohen. Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824.
Cell Cycle. 5:e1-e7, 2006
51. Yongyao Xu, Jennifer L Brogdon, Susanne J Szabo, Shaojian An, Francis Buxton, Dalia Cohen & Qian Huang .Histone deacetylase inhibition specifically impairs innate immune cell control of Th1 effectors cell function. Blood, 109: 1123-1130, 2007
52. N. Rosenfeld1,*, R. Aharonov1,*,†, E. Meiri1, Y. Spector1, S. Rosenwald1, M. Zepeniuk1,H. Benjamin1, N. Shabes1, S. Tabak1, A. Levy1, E. Silberschein1‡, A. Ben-Ari1, S. Gilad1, A. Avniel1, N. Sion Vardy2, O. Nativ3, D. Nass4,5, M. Perelman4,5, A. Yosepovich4,5, B. Shalmon4,5, S. Polak-Charcon4,5, E. Fridman4,5, I. Bentwich1, Z. Bentwich1, D. Cohen1,A. Chajut1 & I. Barshack4,5,† MicroRNAs accurately determine cancer tissue origin. Nature Biotechnology, 26: 462-469, 2008
53. Danit Lebanony ,Hila Benjamin, ,Shlomit Gilad ,Meital Ezagouri ,Avital Dov ,
Karin Ashkenazi ,Nir Gefen ,Shai Izraeli Gideon Rechavi ,Harvey Pass ,Daisuke
Nonaka ,Junjie Li ,Yael Spector ,Nitzan Rosenfeld ,Ayelet Chajut ,Dalia Cohen ,
Ranit Aharonov &Mahesh Mansukhani . A diagnostic assay based on hsa-miR-205 expression distinguishes squamousfrom non-squamous non small-cell lung carcinoma. J. Clinical Oncology. 27(12): 2030, 2009
54. Iris Barshack, Eti Meiri1, Shai Rosenwald, Danit Lebanony, Meital Bronfeld,
Sarit Aviel-Ronen, Kinneret Rosenblatt, Sylvie Polak-Charcon, Ilit Leizerman,
Meital Ezagouri, Merav Zepeniuk, Norberto Shabes, Lahav Cohen, Sarit Tabak,
Dalia Cohen, Zvi Bentwich, Nitzan Rosenfeld. Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. Int J Biochem Cell Biol (2009), 42(8):1355-62, 2009
55. Harvey I. Pass , Chandra Goparaju, Sergey Ivanov, Jessica Donington, Michele Carbone, Moshe Hoshen, Dalia Cohen, Ayelet Chajut , Shai Rosenwald, Harel Dan, Sima Benjamin and Ranit Aharono.. A Single MicroRNA, hsa-mir-29c*,Predicts Progression and Survival for Malignant Pleural Mesothelioma. Cancer Res. 70(5):1916, 2010
56. Sergey V. Ivanov, Chandra M.V. Goparaju, Peter Lopez, Jiri Zavadil, Ginat Toren-Haritan, Shai Rosenwald, Moshe Hosen, Ayelet Chajut, Dalia Cohen, and Harvey I. Pass. Pro- tumorigenic effects of miR -31 loss in mesothelioma. J Biol Chem. 23;285(30):22809-17, 2010
57. Hila Benjamin, Danit Lebanony, Shai Rosenwald, Lahav Cohen, Hadas Gibori, Naama Barabash, Karin Ashkenazi, Eran Goren, Eti Meiri, Sara Morgenstern, Marina Perelman, Iris Barshack, Ilit Leizerman, Ranit Aharonov, Zvi Bentwich, Nitzan Rosenfeld & Dalia Cohen. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. Journal of Molecular Diagnostics 12: 771, 2010
58. Eran Elyakim, Einat Sitbon, Alexander Faerman, Sarit Tabak, Eve Montia, Liron Belanis, Avital Dov, Eric G. Marcusson, C. Frank Bennett, Ayelet Chajut, Dalia Cohen, Noga Yerushalmi. hsa-miR-191 Is a Candidate Oncogene Target for Hepatocellular Carcinoma Therapy. Cancer Research, 15; 70(20):8077-87, 2010
59. Gauri R. Varadhachary, Yael Spector, James L. Abbruzzese, Shai Rosenwald, Huamin Wang, Ranit Aharonov, Heather R. Carlson, Dalia Cohen, Siddharth Karanth, Joanna Macinskas, Renato Lenzi, Ayelet Chajut, Tina B. Edmonston, Martin N. Raber. Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of unknown Primary (CUP). Clinical Cancer Res. April 29, 2011
60. Anthony Greco, Karin Oien, Mark Erlander, Richard Osborne, Gauri Varadhachary, John Bridgewater, Dalia Cohen, Harpreet Wasan, Progress in the Search for Improved and Rapid Diagnosis Leading Toward Superior Patient Outcomes. An of Onc. Vol 23: 98, 2012
61. NANDITA BARNABAS, Dalia Cohen. Phenotypic and Molecular characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. International Journal of Breast Cancer Volume 2013, Article ID 87274 http://dx.doi.org/10.1155/2013/872743,2013
Invited Papers/Reviews
62. Dyer, R. M., Cohen, D. and Herrling, P. L. Building a competitive functional genomics platform. Nature Biotechnology 17 (Supplement) BE18-BE19, 1999
63. Dyer, R. M., Cohen, D. and Herrling, P. L. Functional Genomics: From genes to new therapies. Drug Discovery Today 4: 109-114, 1999
64. Cohen, D. Functional Genomics: A platform for the discovery of new therapies. In: Gene Families: Studies of DNA, RNA, Enzymes and Proteins. Editors: Guoxiong Xue, Yongbiao Xue, Zhihong Xu, Roger Holmes, Graeme L. Hammond & Hwa A. Lim. p179-184, 2001
65. Cohen, D. Breaking the Bottlenecks: Applying Genomics Throughout Drug Discovery and Development, Cambridge Healthtech Institute’s Genomic Reports Series (2001)
66. Kramer, R. and Cohen, D. Functional Genomics: From Genes to New Therapeutics. Medchem News. The Pharmaceutical Society of Japan Division of Medicinal Chemistry, Vol. 12, No. 3, August, 2002
67. Cohen, D. Functionalizing the Genome at Novartis, Israel Venture Capital Journal (IVC J), Vol. 3, No. 1, March 2003
68. Konsolaki,M. and Cohen, D. Review for Targets: Innovations in Genomics & Proteomics: Targets for Alzheimers: lessons learnt from flies, Drug Discovery Today 3; 64-69, 2004
69. Wang, S., Neale, Y.Y., Zeremski, M., Cohen, D, Transcription Regulation by Histone Deacetylases, Novartis Foundation, 2004, Reversible protein acetylation. Wiley, Chichester (Novartis Foundation Symposium 259), pg. 238-248
70. Cohen, D., PharmaTech Series Business Briefing, Future Drug Discovery, 2004
71 . Fischer, V., Einolf, H.J., and Cohen, D., Efflux Transporters and their Clinical Relevance, Communicated in Mini-Review in Medicinal Chemistry, 5:183-195, 2005
72.Kramer, R. and . Cohen, D. Functional genomics to new drug targets. Nature Review Drug Discovery November 965-972, 2004.
73. Rickie, D.O., Wang,S., Cai, R. and Cohen, D. Genomics Approaches To Drug Discovery. Current Opinion In Chemical Biology, 10:303- 308, 2006